Zyvox Cures MRSA Better Than Vancomycin, Study Finds
A new study has confirmed that doctors have an additional last-resort weapon against MRSA-caused skin infections and pneumonia: Pfizer's Zyvox antibiotic, which was released in the US in 2000. A study of 1,180 patients with skin and soft-tissue infections (361 of which were confirmed MRSA)found that Zyvox (linezolid) cured 92%, vs. 88.5% cured by vancomycin (the standard last-resort MRSA treatment). In the confirmed-MRSA subgroup, Zyvox cured 88.6% vs. 66.9% cured by vancomycin.
In addition to the higher cure rate, the study by the Medical College of Wisconsin found that patients taking Zyvox through an IV got off the tube several days earlier (because Zyvox can also be taken orally), which lowered patients' risk of acquiring a new infection via the IV incision.
According to a previous study, the rate of MRSA among [patients with skin and soft-tissue infections] is approximately 30%. Thirty years ago, only 2% of hospital-acquired Staph infections in intensive care units were resistant to antibiotics, but today physicians are seeing rates of approximately 60%.